The results for CD133 demonstrate opposite data to previously described CRC studies and underline the need for its analysis in the context of other relevant molecular biomarkers and tumor/patient characteristics for reliable data interpretation regarding prognostic outcomes. This evidence concerns the gene PROM1 and colorectal carcinoma.